CDK4/6 Inhibition in Early-Stage Breast Cancer: The New Standard?
Mené sur 5 637 patientes atteintes d’un cancer du sein HR+ HER2- de stade précoce, avec atteinte ganglionnaire et à haut risque de récidive, cet essai de phase III évalue l’efficacité, du point de vue de la survie sans maladie invasive, et la toxicité de l’abémaciclib (un inhibiteur anti-CDK4/6) en combinaison avec un traitement endocrinien adjuvant
Adjuvant endocrine therapy, in the form of oral antiestrogens (tamoxifen and aromatase inhibitors) alone or in combination with ovarian function suppression for many younger women, reduces the risk of recurrence and saves lives.1 Many patients with hormone receptor (HR)–positive, early-stage breast cancer will do well with endocrine therapy alone and can safely avoid exposure to the short- and long-term toxicities from adjuvant chemotherapy, especially those with node-negative disease.2,3 Others with higher-risk early-stage disease will benefit from the use of adjuvant chemotherapy in addition to endocrine therapy in this setting. The decision to use adjuvant endocrine therapy alone, or both adjuvant chemotherapy and endocrine therapy, is guided by a combination of clinical and genomic risk4 or just clinical risk including standard high-quality pathology measures